{
    "Trade/Device Name(s)": [
        "MolecularMD MRDx BCR-ABL Test"
    ],
    "Submitter Information": "MolecularMD Corporation",
    "510(k) Number": "K173492",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OYX"
    ],
    "Summary Letter Date": "November 9, 2017",
    "Summary Letter Received Date": "November 13, 2017",
    "Submission Date": "December 20, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.6060"
    ],
    "Regulation Name(s)": [
        "BCR-ABL Quantitation Test"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "hematology"
    ],
    "Analyte(s)": [
        "BCR-ABL1 transcript (e13a2/b2a2, e14a2/b3a2)",
        "ABL1 mRNA"
    ],
    "Specimen Type(s)": [
        "Peripheral blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "PAXgene Blood RNA Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time reverse transcription polymerase chain reaction (RT-qPCR)"
    ],
    "Methodologies": [
        "RT-PCR",
        "Quantitative PCR",
        "Molecular expression testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Software",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for MolecularMD MRDx BCR-ABL Test for quantitative detection of BCR-ABL1 transcripts in peripheral blood of CML patients using RT-qPCR on the Applied Biosystems 7500 Fast Dx platform",
    "Indications for Use Summary": "Quantitative detection of BCR-ABL1 transcripts in peripheral blood from patients with t(9;22) positive chronic myeloid leukemia to monitor treatment with tyrosine kinase inhibitors and aid in identifying patients eligible for treatment discontinuation during nilotinib therapy; not intended for diagnosis of CML.",
    "fda_folder": "Molecular Genetics"
}